Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2018

Open Access 01-03-2018 | Original Research

A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis

Authors: William C. Gordon, Virginia García López, Surjyadipta Bhattacharjee, David Rodríguez Gil, Javier Alcover Díaz, Fernando Pineda de la Losa, Ricardo Palacios Peláez, Concha Tiana Ferrer, Gabriela Silvina Bacchini, Bokkyoo Jun, Hélène Varoqui, Nicolas G. Bazan

Published in: Dermatology and Therapy | Issue 1/2018

Login to get access

Abstract

Introduction

A major clinical challenge in treating allergic contact dermatitis (ACD) is that the first line of treatment is based on the use of corticosteroids. In this study, we aimed to develop a formulation that is devoid of steroids.

Methods

We used mouse ears treated with dinitrofluorobenzene (DNFB) to induce ACD. The efficacy of the test formulation to ameliorate and to prevent induced ACD was determined.

Results

To treat this experimentally induced ACD, we developed a formulation containing BIPxine (a mixture of Rosa moschata and Croton lechleri (antioxidants) and Aloe vera and d-panthenol (moisturizers), and hydroglycolic solutions of disodium cromoglycate. Our results show that clear inhibition of ACD took place. The target of this formulation was PAR-2, TRPV4, and other mediators of the inflammatory and pain responses. However, this formulation must be evaluated in other models besides the mouse to confirm its effectiveness.

Conclusion

The formulation presented here may provide new ACD therapies that do not involve the use of corticosteroids.
Appendix
Available only for authorised users
Literature
1.
2.
Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992;47:65–75.CrossRefPubMed
3.
4.
Tamari M, Tanaka S, Hirota T. Genome-wide association studies of allergic diseases. Allergol Int. 2013;62:21–8.CrossRef
5.
Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–43.CrossRefPubMed
6.
7.
Aquino M, Fonacier L. The role of contact dermatitis in patients with atopic dermatitis. J Allergy Clin Immunol Pract. 2014;2:382–7.CrossRefPubMed
8.
Linauskienė K, Malinauskienė L, Blažienė A. Metals are important contact sensitizers: an experience from Lithuania. Biomed Res Int. 2017;2017:3964045.PubMedPubMedCentral
9.
Lidén C, Yazar K, Johansen JD, Karlberg AT, Uter W, White IR. Comparative sensitizing potencies of fragrances, preservatives, and hair dyes. Contact Dermat. 2016;75:265–75.CrossRef
10.
Kimber I, Basketter DA, Gerberick GF, Dearman RJ. Allergic contact dermatitis. Int Immunopharmacol. 2002;2:201–11.CrossRefPubMed
11.
Keipert JA, Kelly R. Temporary Cushing’s syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust. 1971;1:542–4.PubMed
12.
May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med. 1976;136:612–3.CrossRefPubMed
13.
Munro DD. Topical corticosteroid therapy and its effect on the hypothalamic–pituitary–adrenal axis. Dermatologica. 1976;152:173–80.CrossRefPubMed
14.
Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ, American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818–23.CrossRefPubMed
15.
Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. Cell. 1991;66:807–15.CrossRefPubMed
16.
Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Bürger A, Stütz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol. 2003;149:853–7.CrossRefPubMed
17.
Carvalho RF, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp Dermatol. 2010;19:117–22.CrossRefPubMed
18.
Zhu Y, Wang XR, Peng C, et al. Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. Int Immunopharmacol. 2009;9:1332–6.CrossRefPubMed
19.
Zhu Y, Pan WH, Wang XR, et al. Tryptase and protease-activated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. Int Immunopharmacol. 2015;28:507–12.CrossRefPubMed
20.
White JP, Cibelli M, Urban L, Nilius B, McGeown JG, Nagy I. TRPV4: molecular conductor of a diverse orchestra. Physiol Rev. 2016;96:911–73.CrossRefPubMed
21.
Poole DP, Amadesi S, Veldhuis NA, et al. Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling. J Biol Chem. 2013;288:5790–802.CrossRefPubMedPubMedCentral
22.
Dai Y, Wang S, Tominaga M, et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. J Clin Investig. 2007;117:1979–87.CrossRefPubMedPubMedCentral
23.
Grant AD, Cottrell GS, Amadesi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol. 2007;578:715–33.CrossRefPubMed
24.
25.
Debbasch C, Pisella PJ, Rat P, Warnet JM, Baudouin C. Antioxidant effects of mast cell inhibitors in a human conjunctival cell line. J Fr Ophthalmol. 2001;24:121–8.
26.
Kładna A, Berczyński P, Piechowska T, et al. Studies on the antioxidant activities of some new chromone compounds. Luminescence. 2014;29:846–53.CrossRefPubMed
27.
Jeon YD, Kee JY, Kim DS, et al. Effects of lxeris dentata water extract and caffeic acid on allergic inflammation in vivo and in vitro. BMC Complement Altern Med. 2015;15:196.CrossRefPubMedPubMedCentral
28.
Yuan XY, Ma HM, Li RZ, Wang RY, Liu W, Guo JY. Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. Eur J Pharmacol. 2011;658:263–9.CrossRefPubMed
29.
Bazan NG. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2007;48:4866–81.CrossRefPubMed
30.
Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandin Leukot Essent Fatty Acids. 2009;81:205–11.CrossRef
31.
Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer’s disease. J Lipid Res. 2009;50:S400–5.CrossRefPubMedPubMedCentral
32.
Zhao P, Lieu T, Barlow N, et al. Neutrophil elastase activates protease-activated receptor-2 (PAR2) and transient receptor potential vanilloid 4 (TRPV4) to cause inflammation and pain. J Biol Chem. 2015;290:13875–87.CrossRefPubMedPubMedCentral
33.
Frateschi S, Camerer E, Crisante G, et al. PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat Commun. 2001;2:161.CrossRef
34.
Costa R, Marotta DM, Manjavachi MN, et al. Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. Br J Pharmacol. 2008;154:1094–103.CrossRefPubMedPubMedCentral
35.
Shimada SG, Shimada KA, Collins JG. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. Eur J Pharmacol. 2006;530:281–3.CrossRefPubMed
36.
Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell. 2001;106:619–32.CrossRefPubMed
37.
O’Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275:13502–9.CrossRefPubMed
38.
Liu Q, Weng HJ, Patel KN, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal. 2011;4:ra45.PubMedPubMedCentral
39.
Moormann C, Artuc M, Pohl E, et al. Functional characterization and expression analysis of the protease-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol. 2006;126:746–55.CrossRefPubMed
40.
Harvima IT, Naukkarinen A, Paukkonen K, et al. Mast cell tryptase and chymase in developing and mature psoriatic lesions. Arch Dermatol Res. 1993;285:184–92.CrossRefPubMed
41.
Hou L, Kapas S, Cruchley AT, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology. 1998;94:356–62.CrossRefPubMedPubMedCentral
Metadata
Title
A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis
Authors
William C. Gordon
Virginia García López
Surjyadipta Bhattacharjee
David Rodríguez Gil
Javier Alcover Díaz
Fernando Pineda de la Losa
Ricardo Palacios Peláez
Concha Tiana Ferrer
Gabriela Silvina Bacchini
Bokkyoo Jun
Hélène Varoqui
Nicolas G. Bazan
Publication date
01-03-2018
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2018
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-018-0223-8

Other articles of this Issue 1/2018

Dermatology and Therapy 1/2018 Go to the issue

Case Report

Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report

Original Research

A Qualitative Investigation of the Impact of Acne on Health-Related Quality of Life (HRQL): Development of a Conceptual Model

Case Report

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

Review

Nutraceuticals: A Review

Original Research

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)

Original Research

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits